Bremelanotide Subcutaneous Dosing for Female Sexual Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for female sexual dysfunction (FSD) using melanocortin agonists, such as bremelanotide, often induce adverse cardiovascular effects and other side effects like nausea and vomiting, limiting their therapeutic efficacy.
Innovation Solution
Administering a low dose of bremelanotide via subcutaneous injection, specifically between 1.00 and 1.75 mg, to minimize side effects and optimize peak plasma concentration variability, thereby reducing adverse events like increased blood pressure and nausea.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher doses of bremelanotide are administered to treat FSD, then therapeutic efficacy is improved, but adverse cardiovascular effects and side effects increase
Solution Approach 1:
The patent applies parameter changes by identifying and optimizing the dose parameter, establishing that low doses (0.3-1.0 mg) achieve therapeutic efficacy while minimizing adverse effects. The patent determines through clinical trials that this specific dose range provides sufficient activation of melanocortin receptors for sexual dysfunction treatment without producing excessive cardiovascular stimulation or other harmful effects.
Solution Approach 2:
The patent applies partial action by using sub-therapeutic doses in terms of traditional melanocortin agonist dosing, specifically 0.3-1.0 mg which is lower than conventional doses. This partial dosing strategy achieves sufficient therapeutic effect for FSD while avoiding the excessive action that causes adverse cardiovascular effects at higher doses.
2Reliability
If higher doses of bremelanotide are administered to treat FSD, then therapeutic efficacy is improved, but nausea and vomiting increase
Solution Approach 1:
The patent applies parameter changes by optimizing the dose parameter to 0.3-1.0 mg, which is sufficient to activate melanocortin receptors and improve sexual function while remaining below the threshold that triggers significant nausea and vomiting. Clinical data supports that this dose range maintains therapeutic efficacy without excessive gastrointestinal side effects.
Solution Approach 2:
The patent uses partial action by administering lower than conventional doses of bremelanotide. This partial dosing approach provides adequate therapeutic benefit for female sexual dysfunction while avoiding the excessive stimulation of melanocortin receptors that causes nausea and vomiting at higher doses.
3Ease of operation
If intranasal administration is used, then ease of administration is improved, but peak plasma concentration variability increases
Solution Approach 1:
The patent replaces the intranasal administration mechanism with subcutaneous injection. This substitution eliminates the variability inherent in nasal mucosal absorption while maintaining ease of self-administration. The subcutaneous route provides more consistent and predictable peak plasma concentrations through direct tissue injection, eliminating the mechanical variability of nasal delivery.
4Object-affected harmful factors
If low doses of bremelanotide are administered via subcutaneous injection, then side effects are reduced, but therapeutic efficacy must be optimized
Solution Approach 1:
The patent applies parameter changes by precisely defining the optimal dose parameter range of 0.3-1.0 mg for subcutaneous administration. This parameter optimization ensures that the low dose provides sufficient activation of melanocortin receptors for therapeutic efficacy in FSD while minimizing side effects. The specific dose range was determined through clinical trials balancing efficacy and safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The subcutaneous administration of bremelanotide at low doses effectively treats FSD with reduced side effects compared to intranasal administration, improving sexual function and distress scores while maintaining lower variability in peak plasma concentrations.
Implementation Method 1
agonists of the melanocortin receptor, and particular melanocortin 4 receptor (MC4-R) agonists, may be employed for treatment of sexual dysfunction
Implementation Method 2
administration of a low dose of bremelanotide or a pharmaceutically acceptable salt thereof. The low dose may be administered via subcutaneous injection
Data Source
AI summary
Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.